0001757097--12-312021Q2false6-K2021-06-30Centogene N.V.00017570972021-01-012021-06-300001757097srt:NorthAmericaMembercntg:PharmaceuticalSegmentMember2021-04-012021-06-300001757097srt:NorthAmericaMembercntg:DiagnosticsSegmentMember2021-04-012021-06-300001757097srt:NorthAmericaMembercntg:Covid19Member2021-04-012021-06-300001757097srt:LatinAmericaMembercntg:PharmaceuticalSegmentMember2021-04-012021-06-300001757097srt:LatinAmericaMembercntg:DiagnosticsSegmentMember2021-04-012021-06-300001757097srt:EuropeMembercntg:PharmaceuticalSegmentMember2021-04-012021-06-300001757097srt:EuropeMembercntg:DiagnosticsSegmentMember2021-04-012021-06-300001757097srt:EuropeMembercntg:Covid19Member2021-04-012021-06-300001757097srt:AsiaPacificMembercntg:DiagnosticsSegmentMember2021-04-012021-06-300001757097ifrs-full:PerformanceObligationsSatisfiedOverTimeMembercntg:PharmaceuticalSegmentMember2021-04-012021-06-300001757097ifrs-full:PerformanceObligationsSatisfiedOverTimeMembercntg:DiagnosticsSegmentMember2021-04-012021-06-300001757097ifrs-full:PerformanceObligationsSatisfiedOverTimeMembercntg:Covid19Member2021-04-012021-06-300001757097ifrs-full:PerformanceObligationsSatisfiedAtPointInTimeMembercntg:PharmaceuticalSegmentMember2021-04-012021-06-300001757097ifrs-full:PerformanceObligationsSatisfiedAtPointInTimeMembercntg:Covid19Member2021-04-012021-06-300001757097country:NLcntg:DiagnosticsSegmentMember2021-04-012021-06-300001757097country:NLcntg:Covid19Member2021-04-012021-06-300001757097country:DEcntg:DiagnosticsSegmentMember2021-04-012021-06-300001757097country:DEcntg:Covid19Member2021-04-012021-06-300001757097cntg:IfrsMiddleEastMembercntg:PharmaceuticalSegmentMember2021-04-012021-06-300001757097cntg:IfrsMiddleEastMembercntg:DiagnosticsSegmentMember2021-04-012021-06-300001757097srt:NorthAmericaMember2021-04-012021-06-300001757097srt:LatinAmericaMember2021-04-012021-06-300001757097srt:EuropeMember2021-04-012021-06-300001757097srt:AsiaPacificMember2021-04-012021-06-300001757097ifrs-full:PerformanceObligationsSatisfiedOverTimeMember2021-04-012021-06-300001757097ifrs-full:PerformanceObligationsSatisfiedAtPointInTimeMember2021-04-012021-06-300001757097country:NL2021-04-012021-06-300001757097country:DE2021-04-012021-06-300001757097cntg:PharmaceuticalSegmentMember2021-04-012021-06-300001757097cntg:IfrsMiddleEastMember2021-04-012021-06-300001757097cntg:DiagnosticsSegmentMember2021-04-012021-06-300001757097cntg:Covid19Member2021-04-012021-06-300001757097srt:NorthAmericaMembercntg:PharmaceuticalSegmentMember2021-01-012021-06-300001757097srt:NorthAmericaMembercntg:DiagnosticsSegmentMember2021-01-012021-06-300001757097srt:NorthAmericaMembercntg:Covid19Member2021-01-012021-06-300001757097srt:LatinAmericaMembercntg:PharmaceuticalSegmentMember2021-01-012021-06-300001757097srt:LatinAmericaMembercntg:DiagnosticsSegmentMember2021-01-012021-06-300001757097srt:EuropeMembercntg:PharmaceuticalSegmentMember2021-01-012021-06-300001757097srt:EuropeMembercntg:DiagnosticsSegmentMember2021-01-012021-06-300001757097srt:EuropeMembercntg:Covid19Member2021-01-012021-06-300001757097srt:AsiaPacificMembercntg:DiagnosticsSegmentMember2021-01-012021-06-300001757097srt:AsiaPacificMembercntg:Covid19Member2021-01-012021-06-300001757097ifrs-full:PerformanceObligationsSatisfiedOverTimeMembercntg:PharmaceuticalSegmentMember2021-01-012021-06-300001757097ifrs-full:PerformanceObligationsSatisfiedOverTimeMembercntg:DiagnosticsSegmentMember2021-01-012021-06-300001757097ifrs-full:PerformanceObligationsSatisfiedOverTimeMembercntg:Covid19Member2021-01-012021-06-300001757097ifrs-full:PerformanceObligationsSatisfiedAtPointInTimeMembercntg:PharmaceuticalSegmentMember2021-01-012021-06-300001757097ifrs-full:PerformanceObligationsSatisfiedAtPointInTimeMembercntg:Covid19Member2021-01-012021-06-300001757097country:UScntg:PharmaceuticalSegmentMember2021-01-012021-06-300001757097country:UScntg:DiagnosticsSegmentMember2021-01-012021-06-300001757097country:UScntg:Covid19Member2021-01-012021-06-300001757097country:NLcntg:DiagnosticsSegmentMember2021-01-012021-06-300001757097country:NLcntg:Covid19Member2021-01-012021-06-300001757097country:DEcntg:DiagnosticsSegmentMember2021-01-012021-06-300001757097country:DEcntg:Covid19Member2021-01-012021-06-300001757097cntg:IfrsMiddleEastMembercntg:PharmaceuticalSegmentMember2021-01-012021-06-300001757097cntg:IfrsMiddleEastMembercntg:DiagnosticsSegmentMember2021-01-012021-06-300001757097srt:NorthAmericaMember2021-01-012021-06-300001757097srt:LatinAmericaMember2021-01-012021-06-300001757097srt:EuropeMember2021-01-012021-06-300001757097srt:AsiaPacificMember2021-01-012021-06-300001757097ifrs-full:PerformanceObligationsSatisfiedOverTimeMember2021-01-012021-06-300001757097ifrs-full:PerformanceObligationsSatisfiedAtPointInTimeMember2021-01-012021-06-300001757097country:US2021-01-012021-06-300001757097country:NL2021-01-012021-06-300001757097country:DE2021-01-012021-06-300001757097cntg:PharmaceuticalSegmentMember2021-01-012021-06-300001757097cntg:IfrsMiddleEastMember2021-01-012021-06-300001757097cntg:DiagnosticsSegmentMember2021-01-012021-06-300001757097cntg:Covid19Member2021-01-012021-06-300001757097srt:NorthAmericaMembercntg:PharmaceuticalSegmentMember2020-04-012020-06-300001757097srt:NorthAmericaMembercntg:DiagnosticsSegmentMember2020-04-012020-06-300001757097srt:LatinAmericaMembercntg:DiagnosticsSegmentMember2020-04-012020-06-300001757097srt:EuropeMembercntg:PharmaceuticalSegmentMember2020-04-012020-06-300001757097srt:EuropeMembercntg:DiagnosticsSegmentMember2020-04-012020-06-300001757097srt:EuropeMembercntg:Covid19Member2020-04-012020-06-300001757097srt:AsiaPacificMembercntg:DiagnosticsSegmentMember2020-04-012020-06-300001757097ifrs-full:PerformanceObligationsSatisfiedOverTimeMembercntg:PharmaceuticalSegmentMember2020-04-012020-06-300001757097ifrs-full:PerformanceObligationsSatisfiedOverTimeMembercntg:DiagnosticsSegmentMember2020-04-012020-06-300001757097ifrs-full:PerformanceObligationsSatisfiedOverTimeMembercntg:Covid19Member2020-04-012020-06-300001757097ifrs-full:PerformanceObligationsSatisfiedAtPointInTimeMembercntg:PharmaceuticalSegmentMember2020-04-012020-06-300001757097ifrs-full:PerformanceObligationsSatisfiedAtPointInTimeMembercntg:Covid19Member2020-04-012020-06-300001757097country:UScntg:PharmaceuticalSegmentMember2020-04-012020-06-300001757097country:UScntg:DiagnosticsSegmentMember2020-04-012020-06-300001757097country:SAcntg:DiagnosticsSegmentMember2020-04-012020-06-300001757097country:DEcntg:PharmaceuticalSegmentMember2020-04-012020-06-300001757097country:DEcntg:DiagnosticsSegmentMember2020-04-012020-06-300001757097country:DEcntg:Covid19Member2020-04-012020-06-300001757097cntg:IfrsMiddleEastMembercntg:PharmaceuticalSegmentMember2020-04-012020-06-300001757097cntg:IfrsMiddleEastMembercntg:DiagnosticsSegmentMember2020-04-012020-06-300001757097srt:NorthAmericaMember2020-04-012020-06-300001757097srt:LatinAmericaMember2020-04-012020-06-300001757097srt:EuropeMember2020-04-012020-06-300001757097srt:AsiaPacificMember2020-04-012020-06-300001757097ifrs-full:PerformanceObligationsSatisfiedOverTimeMember2020-04-012020-06-300001757097ifrs-full:PerformanceObligationsSatisfiedAtPointInTimeMember2020-04-012020-06-300001757097country:US2020-04-012020-06-300001757097country:SA2020-04-012020-06-300001757097country:DE2020-04-012020-06-300001757097cntg:PharmaceuticalSegmentMember2020-04-012020-06-300001757097cntg:IfrsMiddleEastMember2020-04-012020-06-300001757097cntg:DiagnosticsSegmentMember2020-04-012020-06-300001757097cntg:Covid19Member2020-04-012020-06-300001757097srt:NorthAmericaMembercntg:PharmaceuticalSegmentMember2020-01-012020-06-300001757097srt:NorthAmericaMembercntg:DiagnosticsSegmentMember2020-01-012020-06-300001757097srt:LatinAmericaMembercntg:DiagnosticsSegmentMember2020-01-012020-06-300001757097srt:EuropeMembercntg:PharmaceuticalSegmentMember2020-01-012020-06-300001757097srt:EuropeMembercntg:DiagnosticsSegmentMember2020-01-012020-06-300001757097srt:EuropeMembercntg:Covid19Member2020-01-012020-06-300001757097srt:AsiaPacificMembercntg:DiagnosticsSegmentMember2020-01-012020-06-300001757097ifrs-full:PerformanceObligationsSatisfiedOverTimeMembercntg:PharmaceuticalSegmentMember2020-01-012020-06-300001757097ifrs-full:PerformanceObligationsSatisfiedOverTimeMembercntg:DiagnosticsSegmentMember2020-01-012020-06-300001757097ifrs-full:PerformanceObligationsSatisfiedOverTimeMembercntg:Covid19Member2020-01-012020-06-300001757097ifrs-full:PerformanceObligationsSatisfiedAtPointInTimeMembercntg:PharmaceuticalSegmentMember2020-01-012020-06-300001757097ifrs-full:PerformanceObligationsSatisfiedAtPointInTimeMembercntg:Covid19Member2020-01-012020-06-300001757097country:UScntg:PharmaceuticalSegmentMember2020-01-012020-06-300001757097country:UScntg:DiagnosticsSegmentMember2020-01-012020-06-300001757097country:SAcntg:DiagnosticsSegmentMember2020-01-012020-06-300001757097country:NLcntg:DiagnosticsSegmentMember2020-01-012020-06-300001757097country:DEcntg:PharmaceuticalSegmentMember2020-01-012020-06-300001757097country:DEcntg:DiagnosticsSegmentMember2020-01-012020-06-300001757097country:DEcntg:Covid19Member2020-01-012020-06-300001757097cntg:IfrsMiddleEastMembercntg:PharmaceuticalSegmentMember2020-01-012020-06-300001757097cntg:IfrsMiddleEastMembercntg:DiagnosticsSegmentMember2020-01-012020-06-300001757097srt:NorthAmericaMember2020-01-012020-06-300001757097srt:LatinAmericaMember2020-01-012020-06-300001757097srt:EuropeMember2020-01-012020-06-300001757097srt:AsiaPacificMember2020-01-012020-06-300001757097ifrs-full:PerformanceObligationsSatisfiedOverTimeMember2020-01-012020-06-300001757097ifrs-full:PerformanceObligationsSatisfiedAtPointInTimeMember2020-01-012020-06-300001757097country:US2020-01-012020-06-300001757097country:SA2020-01-012020-06-300001757097country:NL2020-01-012020-06-300001757097country:DE2020-01-012020-06-300001757097cntg:PharmaceuticalSegmentMember2020-01-012020-06-300001757097cntg:IfrsMiddleEastMember2020-01-012020-06-300001757097cntg:DiagnosticsSegmentMember2020-01-012020-06-300001757097cntg:Covid19Member2020-01-012020-06-300001757097cntg:StateOfMecklenburgWesternPomeraniaMember2021-01-012021-06-300001757097country:US2021-06-300001757097country:US2020-12-310001757097cntg:Covid19SegmentPartnerTwoMembercntg:Covid19Member2021-04-012021-06-300001757097cntg:Covid19SegmentPartnerOneMembercntg:Covid19Member2021-04-012021-06-300001757097cntg:Covid19SegmentPartnerTwoMembercntg:Covid19Member2021-01-012021-06-300001757097cntg:Covid19SegmentPartnerOneMembercntg:Covid19Member2021-01-012021-06-300001757097cntg:PharmaceuticalPartnerMembercntg:PharmaceuticalSegmentMember2020-04-012020-06-300001757097cntg:Covid19SegmentPartnerMembercntg:Covid19Member2020-04-012020-06-300001757097cntg:PharmaceuticalPartnerMembercntg:PharmaceuticalSegmentMember2020-01-012020-06-300001757097cntg:Covid19SegmentPartnerMembercntg:Covid19Member2020-01-012020-06-300001757097ifrs-full:OrdinarySharesMember2021-06-300001757097ifrs-full:OrdinarySharesMember2020-12-310001757097cntg:EquityShareOption2017EquitySettledMember2021-01-012021-06-300001757097cntg:StockOptionsMembercntg:LongTermIncentivePlanMember2020-12-310001757097cntg:EquityShareOption2017EquitySettledMember2020-12-310001757097cntg:IfrsRestrictedStockUnitsRsusMembercntg:LongTermIncentivePlanMember2020-12-310001757097cntg:IfrsRestrictedStockUnitsRsusMembercntg:LongTermIncentivePlanMember2021-01-012021-06-300001757097cntg:IfrsChiefExecutiveOfficerMember2020-12-012020-12-010001757097cntg:LpcGmbhMember2020-06-300001757097ifrs-full:CapitalReserveMember2020-01-012020-06-300001757097cntg:FollowOnEquityOfferingMembercntg:SellingShareholdersMemberifrs-full:OrdinarySharesMemberifrs-full:MajorPurchasesOfAssetsMember2020-07-012020-07-310001757097cntg:FollowOnEquityOfferingMembercntg:CentogeneN.vMemberifrs-full:OrdinarySharesMemberifrs-full:MajorPurchasesOfAssetsMember2020-07-012020-07-310001757097cntg:SecuredBankLoanMember2021-06-300001757097cntg:SecuredBankLoanMember2020-12-310001757097cntg:OverdraftFacilityOneMember2020-12-310001757097cntg:UnallocatedAmountsShareBasedPaymentsMember2021-04-012021-06-300001757097cntg:UnallocatedAmountsShareBasedPaymentsMember2021-01-012021-06-300001757097cntg:UnallocatedAmountsShareBasedPaymentsMember2020-04-012020-06-300001757097cntg:UnallocatedAmountsShareBasedPaymentsMember2020-01-012020-06-300001757097cntg:TradeReceivablesAndContractAssetsMemberifrs-full:NotLaterThanOneMonthMember2021-06-300001757097cntg:TradeReceivablesAndContractAssetsMemberifrs-full:LaterThanThreeMonthsMember2021-06-300001757097cntg:TradeReceivablesAndContractAssetsMemberifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember2021-06-300001757097cntg:TradeReceivablesAndContractAssetsMemberifrs-full:CurrentMember2021-06-300001757097cntg:TradeReceivablesAndContractAssetsMemberifrs-full:NotLaterThanOneMonthMember2020-12-310001757097cntg:TradeReceivablesAndContractAssetsMemberifrs-full:LaterThanThreeMonthsMember2020-12-310001757097cntg:TradeReceivablesAndContractAssetsMemberifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember2020-12-310001757097cntg:TradeReceivablesAndContractAssetsMemberifrs-full:CurrentMember2020-12-310001757097cntg:PartneringLaboratoryPhysicianProfDrPeterBauerMembercntg:AssociationOfStatutoryHealthInsurancePhysiciansMember2021-08-070001757097ifrs-full:RetainedEarningsMember2021-06-300001757097ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2021-06-300001757097ifrs-full:NoncontrollingInterestsMember2021-06-300001757097ifrs-full:IssuedCapitalMember2021-06-300001757097ifrs-full:EquityAttributableToOwnersOfParentMember2021-06-300001757097ifrs-full:CapitalReserveMember2021-06-300001757097ifrs-full:RetainedEarningsMember2020-12-310001757097ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2020-12-310001757097ifrs-full:NoncontrollingInterestsMember2020-12-310001757097ifrs-full:IssuedCapitalMember2020-12-310001757097ifrs-full:EquityAttributableToOwnersOfParentMember2020-12-310001757097ifrs-full:CapitalReserveMember2020-12-310001757097ifrs-full:RetainedEarningsMember2020-06-300001757097ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2020-06-300001757097ifrs-full:NoncontrollingInterestsMember2020-06-300001757097ifrs-full:IssuedCapitalMember2020-06-300001757097ifrs-full:EquityAttributableToOwnersOfParentMember2020-06-300001757097ifrs-full:CapitalReserveMember2020-06-300001757097ifrs-full:RetainedEarningsMember2019-12-310001757097ifrs-full:NoncontrollingInterestsMember2019-12-310001757097ifrs-full:IssuedCapitalMember2019-12-310001757097ifrs-full:EquityAttributableToOwnersOfParentMember2019-12-310001757097ifrs-full:CapitalReserveMember2019-12-310001757097cntg:UnallocatedAmountsDepreciationAndAmortizationMember2021-04-012021-06-300001757097cntg:UnallocatedAmountsDepreciationAndAmortizationMember2021-01-012021-06-300001757097cntg:UnallocatedAmountsDepreciationAndAmortizationMember2020-04-012020-06-300001757097cntg:UnallocatedAmountsDepreciationAndAmortizationMember2020-01-012020-06-300001757097ifrs-full:RetainedEarningsMember2021-01-012021-06-300001757097ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2021-01-012021-06-300001757097ifrs-full:NoncontrollingInterestsMember2021-01-012021-06-300001757097ifrs-full:IssuedCapitalMember2021-01-012021-06-300001757097ifrs-full:EquityAttributableToOwnersOfParentMember2021-01-012021-06-300001757097ifrs-full:CapitalReserveMember2021-01-012021-06-300001757097ifrs-full:RetainedEarningsMember2020-01-012020-06-300001757097ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2020-01-012020-06-300001757097ifrs-full:NoncontrollingInterestsMember2020-01-012020-06-300001757097ifrs-full:EquityAttributableToOwnersOfParentMember2020-01-012020-06-3000017570972020-06-3000017570972019-12-310001757097ifrs-full:LeaseLiabilitiesMemberifrs-full:TopOfRangeMember2021-06-300001757097ifrs-full:LeaseLiabilitiesMemberifrs-full:BottomOfRangeMember2021-06-300001757097cntg:OtherBankLoansMember2021-06-300001757097ifrs-full:LeaseLiabilitiesMemberifrs-full:TopOfRangeMember2020-12-310001757097ifrs-full:LeaseLiabilitiesMemberifrs-full:BottomOfRangeMember2020-12-310001757097cntg:TradeReceivablesAndContractAssetsMember2021-06-300001757097cntg:TradeReceivablesAndContractAssetsMember2020-12-310001757097cntg:LongTermIncentivePlanMember2021-04-012021-06-300001757097cntg:RostockHeadquartersBuildingMemberifrs-full:NotLaterThanOneYearMember2021-06-300001757097cntg:RostockHeadquartersBuildingMemberifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember2021-06-300001757097cntg:RostockHeadquartersBuildingMemberifrs-full:LaterThanFiveYearsMember2021-06-300001757097cntg:OfficeEquipmentAndStorageSpacesMemberifrs-full:NotLaterThanOneYearMember2021-06-300001757097cntg:OfficeEquipmentAndStorageSpacesMemberifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember2021-06-300001757097cntg:RostockHeadquartersBuildingMemberifrs-full:NotLaterThanOneYearMember2020-12-310001757097cntg:RostockHeadquartersBuildingMemberifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember2020-12-310001757097cntg:RostockHeadquartersBuildingMemberifrs-full:LaterThanFiveYearsMember2020-12-310001757097cntg:OfficeEquipmentAndStorageSpacesMemberifrs-full:NotLaterThanOneYearMember2020-12-310001757097cntg:OfficeEquipmentAndStorageSpacesMemberifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember2020-12-310001757097cntg:StockOptionsMembercntg:LongTermIncentivePlanMember2021-01-012021-06-300001757097cntg:StockOptionsMember2021-01-012021-06-300001757097cntg:FollowOnEquityOfferingMemberifrs-full:OrdinarySharesMemberifrs-full:MajorPurchasesOfAssetsMember2020-07-012020-07-310001757097cntg:OverdraftFacilityMember2021-06-300001757097cntg:OverdraftFacilityMember2020-12-310001757097ifrs-full:OtherAssetsMemberifrs-full:OtherPropertyPlantAndEquipmentMember2021-06-300001757097ifrs-full:TopOfRangeMember2021-01-012021-06-300001757097ifrs-full:BottomOfRangeMember2021-01-012021-06-300001757097cntg:IfrsRestrictedStockUnitsRsusMembersrt:ManagementMembercntg:GrantOfRestrictedStockUnitsMembercntg:LongTermIncentivePlanMembercntg:VestingInFourTranchesMember2021-07-012021-09-300001757097cntg:StockOptionsMembercntg:LongTermIncentivePlanMembercntg:VestingInThreeTranchesMember2021-06-300001757097cntg:StockOptionsMembercntg:LongTermIncentivePlanMember2021-06-300001757097cntg:EquityShareOption2017EquitySettledMember2021-06-300001757097cntg:IfrsRestrictedStockUnitsRsusMembercntg:LongTermIncentivePlanMember2021-06-300001757097cntg:PharmaceuticalPartnerMembercntg:PharmaceuticalSegmentMember2021-04-012021-06-300001757097cntg:Covid19SegmentPartnerMembercntg:Covid19Member2021-04-012021-06-300001757097cntg:PharmaceuticalPartnerMembercntg:PharmaceuticalSegmentMember2021-01-012021-06-300001757097cntg:Covid19SegmentPartnerMembercntg:Covid19Member2021-01-012021-06-300001757097cntg:IfrsRestrictedStockUnitsRsusMembercntg:IfrsChiefExecutiveOfficerMember2020-12-012020-12-010001757097cntg:RsuGrantedThreeMember2021-01-012021-06-300001757097cntg:LongTermIncentivePlanMember2021-01-012021-06-300001757097cntg:IfrsRestrictedStockUnitsRsusMembersrt:ManagementMembercntg:GrantOfRestrictedStockUnitsMembercntg:LongTermIncentivePlanMember2021-07-012021-09-300001757097cntg:RsuGrantedTwoMember2021-01-012021-06-300001757097cntg:RsuGrantedOneMember2021-01-012021-06-300001757097cntg:OptionsGrantedTwoMember2021-01-012021-06-300001757097cntg:OptionsGrantedOneMember2021-01-012021-06-300001757097cntg:OverdraftFacilityTwoMember2021-06-300001757097cntg:OverdraftFacilityOneMember2021-06-3000017570972020-01-012020-12-310001757097cntg:SecuredBankLoansWithMaturityPeriod2017To22Member2021-06-300001757097cntg:BankOverdraftsTwoMember2021-06-300001757097cntg:BankOverdraftsThreeMember2021-06-300001757097cntg:BankOverdraftsOneMember2021-06-300001757097cntg:SecuredBankLoansWithMaturityPeriod2017To22Member2020-12-310001757097cntg:BankOverdraftsTwoMember2020-12-310001757097cntg:BankOverdraftsThreeMember2020-12-310001757097cntg:BankOverdraftsOneMember2020-12-310001757097cntg:UniversitairMedischCentrumUtrechtMember2021-06-300001757097cntg:StateOfMecklenburgWesternPomeraniaMember2021-06-300001757097cntg:UniversitairMedischCentrumUtrechtMember2018-11-080001757097ifrs-full:OtherAssetsMember2021-06-300001757097ifrs-full:OtherAssetsMember2020-12-310001757097ifrs-full:LeaseLiabilitiesMember2021-06-300001757097ifrs-full:BorrowingsByNameMember2021-06-300001757097cntg:SecuredCreditLinesMember2021-06-300001757097cntg:IfrsBankOverdraftsMember2021-06-3000017570972021-06-300001757097ifrs-full:LeaseLiabilitiesMember2020-12-310001757097ifrs-full:BorrowingsByNameMember2020-12-310001757097cntg:SecuredCreditLinesMember2020-12-310001757097cntg:OtherBankLoansMember2020-12-310001757097cntg:IfrsBankOverdraftsMember2020-12-3100017570972020-12-310001757097ifrs-full:OtherAssetsMembercntg:LpcGmbhMember2021-06-300001757097cntg:LpcGmbhMember2020-01-012020-06-300001757097ifrs-full:PropertyPlantAndEquipmentMembercountry:DEcntg:Covid19Member2021-04-012021-06-300001757097ifrs-full:IntangibleAssetsOtherThanGoodwillMembercountry:DEcntg:Covid19Member2021-04-012021-06-300001757097ifrs-full:PropertyPlantAndEquipmentMembercountry:DEcntg:Covid19Member2021-01-012021-06-300001757097ifrs-full:IntangibleAssetsOtherThanGoodwillMembercountry:DEcntg:Covid19Member2021-01-012021-06-300001757097ifrs-full:PropertyPlantAndEquipmentMembercountry:DEcntg:Covid19Member2020-04-012020-06-300001757097ifrs-full:IntangibleAssetsOtherThanGoodwillMembercountry:DEcntg:Covid19Member2020-04-012020-06-300001757097ifrs-full:PropertyPlantAndEquipmentMembercountry:DEcntg:Covid19Member2020-01-012020-06-300001757097ifrs-full:IntangibleAssetsOtherThanGoodwillMembercountry:DEcntg:Covid19Member2020-01-012020-06-300001757097ifrs-full:OtherAssetsMembercntg:RostockHeadquartersBuildingMember2021-06-300001757097ifrs-full:OtherAssetsMembercntg:BerlinOfficesMember2021-06-300001757097ifrs-full:OrdinarySharesMember2021-01-012021-06-300001757097ifrs-full:OrdinarySharesMember2020-01-012020-12-310001757097ifrs-full:OperatingSegmentsMember2021-04-012021-06-300001757097ifrs-full:OperatingSegmentsMember2021-01-012021-06-300001757097ifrs-full:OperatingSegmentsMember2020-04-012020-06-300001757097ifrs-full:OperatingSegmentsMember2020-01-012020-06-300001757097ifrs-full:OperatingSegmentsMembercntg:DiagnosticsSegmentMember2021-04-012021-06-300001757097ifrs-full:OperatingSegmentsMembercntg:PharmaceuticalSegmentMember2021-04-012021-06-300001757097ifrs-full:OperatingSegmentsMembercntg:Covid19Member2021-04-012021-06-300001757097cntg:IfrsCorporateMember2021-04-012021-06-3000017570972021-04-012021-06-300001757097ifrs-full:OperatingSegmentsMembercntg:PharmaceuticalSegmentMember2021-01-012021-06-300001757097ifrs-full:OperatingSegmentsMembercntg:DiagnosticsSegmentMember2021-01-012021-06-300001757097ifrs-full:OperatingSegmentsMembercntg:Covid19Member2021-01-012021-06-300001757097cntg:IfrsCorporateMember2021-01-012021-06-300001757097ifrs-full:OperatingSegmentsMembercntg:PharmaceuticalSegmentMember2020-04-012020-06-300001757097ifrs-full:OperatingSegmentsMembercntg:DiagnosticsSegmentMember2020-04-012020-06-300001757097ifrs-full:OperatingSegmentsMembercntg:Covid19Member2020-04-012020-06-300001757097cntg:IfrsCorporateMember2020-04-012020-06-3000017570972020-04-012020-06-300001757097ifrs-full:OperatingSegmentsMembercntg:PharmaceuticalSegmentMember2020-01-012020-06-300001757097ifrs-full:OperatingSegmentsMembercntg:DiagnosticsSegmentMember2020-01-012020-06-300001757097ifrs-full:OperatingSegmentsMembercntg:Covid19Member2020-01-012020-06-300001757097cntg:IfrsCorporateMember2020-01-012020-06-3000017570972020-01-012020-06-30cntg:Optionsiso4217:EURiso4217:CHFcntg:customerxbrli:sharescntg:trancheiso4217:EURxbrli:sharesiso4217:USDxbrli:sharesxbrli:pureiso4217:USD

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the date of September 7, 2021

Commission File Number 001-39124

Centogene N.V.

(Translation of registrant’s name into English)

Am Strande 7

18055 Rostock

Germany

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F.... Form 40-F.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Centogene N.V.

On September 7, 2021, Centogene N.V. (the “Company”) issued a press release reporting its financial results for the six months ended June 30, 2021. A copy of the press release is attached hereto as Exhibit 99.1.

Attached hereto as Exhibits 99.2 and 99.3 are also the financial statements of the Company for the three and six months ended June 30, 2021 and the Management’s Discussion and Analysis of Financial Condition and Results of Operations for the three and six months ended June 30, 2021, respectively. All exhibits attached hereto are incorporated by reference herein.

Exhibit 99.1 to this Report on Form 6-K shall not be deemed “filed” for purposes of Section 18 of the U.S. Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the U.S. Securities Act of 1933, as amended, or the Exchange Act.

Exhibits 99.2 and 99.3 to this Report on Form 6-K shall be deemed to be incorporated by reference into the registration statement on Form S-8 (Registration Number 333-234551) of the Company and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

2

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

CENTOGENE N.V.

Date: September 7, 2021

By:

/s/ Rene Just

Name:

Rene Just

Title:

Chief Financial Officer

3

Exhibit Index

Exhibit

    

Description of Exhibit

99.1

Press Release dated September 7, 2021

99.2

Unaudited Condensed Consolidated Interim Financial Statements as of and for the Three and Six Months ended June 30, 2021

99.3

Management’s Discussion and Analysis of Financial Condition and Results of Operations for the Three and Six Months ended June 30, 2021

4